MOTS-c: Metabolism, Benefits and FDA Status

Medically reviewed by Amber Patel, MD. Nouri content is reviewed by licensed clinicians and updated as guidance changes.

What is MOTS-c?

MOTS-c stands for "mitochondrial open reading frame of the twelve S rRNA type-c." It is a short peptide — 16 amino acids — that is unusual because it is encoded not in the cell's main nuclear DNA but inside the mitochondrial genome. Mitochondria are the structures that turn food into usable energy, and MOTS-c is one of a small family of "mitochondrial-derived peptides" that appear to act as signaling molecules between the mitochondria and the rest of the cell.

MOTS-c was first described in 2015 by researchers at USC, who reported that in mice it activated an energy-sensing enzyme called AMPK and appeared to influence how the body handles glucose and fat (Lee et al., Cell Metabolism 2015). Since then it has drawn interest as a possible regulator of metabolism and aging. It is important to be precise about what that interest rests on: the bulk of the MOTS-c literature is laboratory and animal work, with human data limited to observations of naturally occurring MOTS-c levels rather than trials that gave MOTS-c to people as a therapy.

What has research investigated about MOTS-c and metabolism?

Most of the excitement around MOTS-c comes from its role in metabolism. Here is what the research has actually investigated — framed as what the studies looked at, not as proven human benefits.

• Obesity and metabolic homeostasis. In the original discovery paper, mice given MOTS-c were protected from diet-induced obesity, and the peptide appeared to promote metabolic balance (Lee et al., 2015). This was a mouse finding.
• Insulin sensitivity. The same line of research reported that MOTS-c reversed age- and diet-related insulin resistance in mice, an effect tied to AMPK activation (Lee et al., Free Radic Biol Med 2016).
• Exercise capacity — the "exercise mimetic" idea. A 2021 study found that MOTS-c improved running capacity in aged mice and that exercise itself raises MOTS-c levels in human muscle (Reynolds et al., Nature Communications 2021). The human part of that study measured expression — how much MOTS-c the body makes — not the effect of taking MOTS-c.
• Cellular stress and mitochondrial signaling. In cell studies, MOTS-c moves into the nucleus under metabolic stress and helps switch on antioxidant genes through the NRF2 pathway, in an AMPK-dependent way (Kim et al., Cell Metabolism 2018).

A 2023 mechanism review summarizing this field is blunt about the evidence base: the data come from cell and animal experiments plus human observational studies, not from intervention trials in people (Wan et al., J Transl Med 2023). To say it plainly: human clinical evidence for MOTS-c is very limited, and no randomized trial has shown that giving MOTS-c to people improves metabolism, insulin sensitivity, or weight. Anti-doping authority USADA likewise classifies MOTS-c as experimental (USADA).

What are the reported MOTS-c benefits — and how solid are they?

When people search for "MOTS-c benefits," they usually mean fat loss, better blood sugar, more energy, and improved exercise performance. Each of those maps to a line of preclinical research above. The honest summary is that these are hypotheses generated by animal and cell studies, not benefits demonstrated in human trials.

Claimed benefit	What the research actually shows	Evidence level
Weight / fat loss	Prevented diet-induced obesity in mice (Lee 2015)	Animal only
Improved insulin sensitivity	Reversed insulin resistance in mice via AMPK (Lee 2016)	Animal only
"Exercise mimetic" / endurance	Improved running capacity in aged mice; exercise raises MOTS-c in human muscle (Reynolds 2021)	Animal + human observational (levels)
Antioxidant / cellular stress defense	Activated NRF2 antioxidant genes in cells (Kim 2018)	Cell only

What is the FDA status of MOTS-c?

MOTS-c is not an approved drug. It is not FDA-approved for any use, and it is not on the FDA's 503A Bulks List — the list of substances that compounding pharmacies are permitted to use. In practical terms, there is no legal path to compound, prescribe, or buy MOTS-c in the United States today.

MOTS-c (in its free base and acetate forms) was reviewed on Day 1 of the FDA Pharmacy Compounding Advisory Committee meeting held July 23-24, 2026 (docket FDA-2025-N-6895; FDA meeting page). FDA staff proposed not to add MOTS-c to the 503A Bulks List. That is a proposal, and the committee is advisory — its recommendations are non-binding, and even a positive vote would only start a rulemaking process rather than create a legal path on its own. Nothing about this meeting made MOTS-c legally available. Anything sold as MOTS-c today comes from the unregulated "research chemical" gray market, where identity, purity, and sterility are not verified to pharmacy standards.

What is the MOTS-c dosage?

There is no established clinical dose for MOTS-c. It has no FDA-approved label, and no validated human dosing trial exists to anchor a recommendation. Materials from vendors and research-context write-ups describe the landscape as roughly 5-10 mg per week given subcutaneously over short cycles of about 4-8 weeks, with an animal half-life measured in a few hours. Those figures come from unregulated sources and are not clinically validated; they describe what is circulating, not what is safe or effective.

This is a genuine safety issue, not a formality. "Research use only" material does not meet pharmaceutical manufacturing standards, so purity and sterility are unverified. There is a theoretical risk of low blood sugar if a metabolically active peptide were combined with glucose-lowering medications, and MOTS-c is prohibited or monitored in sport by anti-doping authorities. Because there is no legal, verified product, this article does not and will not provide reconstitution steps, injection math, or a dosing protocol.

MOTS-c vs semaglutide — and is MOTS-c a GLP-1?

These come up constantly, so let's answer them directly. MOTS-c is not a GLP-1, and it is not the same thing as semaglutide. They are different molecules that work through different biology.

MOTS-c is a mitochondrial-derived peptide studied mainly in animals for its effects on mitochondrial signaling and the AMPK energy pathway. GLP-1 and GLP-1/GIP medicines — semaglutide and tirzepatide — are incretin-based drugs that act largely on appetite and satiety, and they have been tested in large Phase 3 human trials. So they are not interchangeable, and MOTS-c is not a natural or mechanistic substitute for a GLP-1. The decisive practical difference is evidence and legality: semaglutide and tirzepatide have human trial data and are prescribable through licensed clinicians, while MOTS-c has neither human efficacy data nor a legal path.

If your real goal is metabolic health and weight, here's the legal path

Most people reading about MOTS-c aren't after a lab curiosity — they want better metabolic health and, often, weight loss. That's a reasonable goal. The problem is that MOTS-c can't get you there today: it isn't proven in humans and it isn't legally available. So it's worth knowing what is both evidence-backed and legally available in metabolic medicine.

The category with strong human evidence for weight management is GLP-1/GIP medicines. In the STEP-1 trial, adults taking semaglutide 2.4 mg lost a mean of −14.9% of body weight versus −2.4% on placebo at 68 weeks (Wilding et al., NEJM 2021). In SURMOUNT-1, tirzepatide produced mean weight reductions of up to −20.9% to −22.5% at 72 weeks (Jastreboff et al., NEJM 2022). Those are Phase 3 trials in people — a different world from mouse data.

Two things must be crystal clear. First, those trials studied the molecules — semaglutide (the active ingredient in Wegovy and Ozempic) and tirzepatide (in Zepbound and Mounjaro) — not any Nouri product; they are evidence about the molecule, and results from a branded trial do not automatically carry over to a compounded preparation. Second, compounded semaglutide and tirzepatide are not FDA-approved and are not therapeutically equivalent to Wegovy, Ozempic, Zepbound, or Mounjaro. And these medicines are not a MOTS-c substitute — they work on appetite and satiety, a different mechanism entirely. They are simply the metabolic-medicine category that actually has human evidence and a licensed route.

If you're curious about how peptides are studied and why sourcing matters, our explainer on what BPC-157 is and what the research says covers another widely discussed research peptide and the same gray-market caution.

How Nouri fits in

Nouri is a licensed US telehealth brand built around metabolic health, not gray-market peptides. Our weight-loss program is anchored in the GLP-1/GIP category described above, with medication prescribed and overseen by licensed clinicians after a medical review. The program is all-inclusive: any dose is the same price at a given plan length.

Compounded semaglutide is $120/month on the 6-month plan ($720), $145/month on the 3-month plan ($435), or $175/month monthly. Compounded tirzepatide is $175/month on the 6-month plan ($1,050), $199/month on the 3-month plan ($597), or $225/month monthly. Every plan is backed by the Nouri Promise: a 30-day money-back guarantee — a full refund on the 3-month and 6-month plans.

To be transparent, as required and because it's the honest framing: compounded semaglutide and tirzepatide are not FDA-approved and are not therapeutically equivalent to Wegovy, Ozempic, Zepbound, or Mounjaro. Whether a GLP-1 program is appropriate is a decision to make with a clinician based on your health.

If and when licensed peptide options ever become available, we'll offer a way to hear about it. You can join the Nouri peptide waitlist to be first to know if that changes — there's nothing to buy, and no availability date is implied.

Frequently asked questions

Is MOTS-c FDA-approved? No. MOTS-c is not FDA-approved and is not on the FDA 503A Bulks List, so there is no legal path to compound, prescribe, or buy it today. FDA staff reviewed MOTS-c at the July 23-24, 2026 Pharmacy Compounding Advisory Committee and proposed not to add it to the list. That committee is advisory and non-binding.

Does MOTS-c cause weight loss in humans? There is no human trial evidence that MOTS-c causes weight loss. In mice, MOTS-c prevented diet-induced obesity and improved insulin resistance, and it activates the AMPK metabolic pathway in cells. Human data is limited to observational studies of naturally occurring MOTS-c levels, not clinical trials of MOTS-c as a treatment.

Is MOTS-c the same as a GLP-1 like semaglutide? No. MOTS-c and GLP-1 medicines are different molecules with different mechanisms. MOTS-c is a mitochondrial-derived peptide studied mainly in animals. GLP-1/GIP medicines such as semaglutide and tirzepatide act on appetite and satiety and have Phase 3 human trials for weight management. MOTS-c is not a GLP-1 and is not a substitute for one.

What is the MOTS-c dosage? There is no established clinical dose for MOTS-c. It has no FDA label and no validated human dosing trial. Vendor and research-context materials describe roughly 5-10 mg per week over short cycles, but those figures are not clinically validated and come from unregulated sources. Because MOTS-c has no legal path today, there is no verified, pharmacy-grade product to dose.

Is MOTS-c banned in sport? MOTS-c is treated as experimental and is prohibited or monitored in sport by anti-doping authorities such as USADA. It is not an approved therapy, and athletes subject to anti-doping rules should not use it.

What is a legal, evidence-backed option for metabolic health and weight? GLP-1/GIP medicines are the category with strong Phase 3 human evidence for weight management. Nouri runs a licensed telehealth weight-loss program built around compounded semaglutide and tirzepatide, with clinician oversight. Compounded semaglutide and tirzepatide are not FDA-approved and are not therapeutically equivalent to Wegovy, Ozempic, Zepbound, or Mounjaro.

Sources & data

Primary sources, each linked:

• Lee C, et al. MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism, 2015. PMID 25738459 (Tier 1)
• Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator. Nature Communications, 2021. PMID 33473109 (Tier 1)
• Kim KH, et al. MOTS-c translocates to the nucleus to regulate gene expression under metabolic stress. Cell Metabolism, 2018. PMID 29983246 (Tier 1)
• Lee C, et al. MOTS-c: regulating muscle and fat metabolism (review). Free Radic Biol Med, 2016. PMID 27216708 (Tier 1)
• Wan W, et al. Mitochondria-derived peptide MOTS-c: effects and mechanisms (review). J Transl Med, 2023. PMC9854231 (Tier 1)
• USADA. What is the MOTS-c peptide? USADA Spirit of Sport (Tier 2)
• FDA. July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting (docket FDA-2025-N-6895). FDA advisory calendar (Tier 2)
• Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP-1). NEJM, 2021;384:989-1002. PMID 33567185 (Tier 1, molecule evidence)
• Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). NEJM, 2022;387:205-216. PMID 35658024 (Tier 1, molecule evidence)

The STEP-1 and SURMOUNT-1 results describe the semaglutide and tirzepatide molecules studied in those trials, not any Nouri product. Compounded semaglutide and tirzepatide are not FDA-approved and are not therapeutically equivalent to Wegovy, Ozempic, Zepbound, or Mounjaro. This article is educational and is not medical advice.

Ready to focus on metabolic health with an evidence-backed, legally available option? Start your visit with Nouri — see if you qualify in about five minutes.